Calida Therapeutics is a technology company.
Calida Therapeutics has raised $2.0M across 1 funding round.
Calida Therapeutics has raised $2.0M in total across 1 funding round.
Calida Therapeutics is a preclinical-stage biotechnology company developing monoclonal antibodies to treat and prevent thrombo-inflammatory disorders, such as deep vein thrombosis, stroke, atherosclerosis, and complications from infectious or autoimmune diseases.[1][2] Incorporated in Paris, France, it targets the molecular link between thrombosis and inflammation by blocking crosstalk between platelets and myeloid cells, aiming to halt tissue damage and life-threatening events.[1][2] The company has raised €2 million ($2.17 million) in seed funding from AdBio Partners and BioMotiv to advance in vivo proofs of concept and select a lead candidate, positioning it for growth in a field affecting millions worldwide.[1][2][4]
Calida Therapeutics was co-founded in December 2022 by Dr. Daniel Simon (MD, PhD), Dr. Edward Plow (PhD), and Dr. Yunmei Wang (PhD), alongside venture capital funds BioMotiv and AdBio Partners.[1][2] The idea stems from over 20 years of research in Cleveland, Ohio, by these academic and medical experts, who identified platelets' role in inflammation beyond traditional cardiovascular contexts—a novel paradigm unaddressed by existing therapies.[1][2] Clément Bertholet serves as CEO, leading a team of biotech veterans to translate this U.S.-based science into European development.[2] Early traction includes the €2 million seed round upon launch, funding initial preclinical validation.[1][2]
Calida rides the thrombo-inflammation trend, redefining inflammation as platelet-dependent and expanding beyond cardiology to immunology and infectious diseases amid rising chronic condition prevalence.[1][2] Timing aligns with post-pandemic focus on vascular complications and antibody therapeutics' maturity, fueled by AI-driven discovery advances.[1] Market forces like unmet needs in stroke prevention and autoimmune therapies favor its approach, while Paris's biotech hub strengthens EU funding access.[2][4] By pioneering this paradigm, Calida influences ecosystem shifts toward integrated thrombosis-inflammation targets, potentially inspiring similar cross-disciplinary biotech ventures.[1][2]
Calida's next milestones include selecting a lead monoclonal antibody candidate and advancing to IND-enabling studies, building on seed validation.[1][2] Trends like precision immunology and combo therapies for vascular-autoimmune overlaps will shape its path, with potential for partnerships as preclinical data emerges. Its influence may grow by validating thrombo-inflammation as a blockbuster field, evolving from niche innovator to category leader—echoing its launch promise to transform treatments for millions.[1][2]
Calida Therapeutics has raised $2.0M in total across 1 funding round.
Calida Therapeutics's investors include Advent Life Sciences.
Calida Therapeutics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $2.0M Seed | Advent Life Sciences |